2012 Current Cancer Dedicated to bringing the latest news and information on cancer diagnosis, treatment and prevention.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Avastin (bevacizumab) in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line (first-line following surgery) treatment for women with advanced ovarian cancer. Ovarian cancer is the most deadly of the gynaecological cancers, with approximately 220,000 women diagnosed and 140,000 women ...

he clinical and cost effectiveness of two breast cancer drugs that may be offered alongside hormone therapy to some postmenopausal women who have a particular type of the disease has not been clearly demonstrated. Draft guidance from the National Institute for Health and Clinical Excellence (NICE) therefore recommends against their use in the NHS for ...

In a recent study (1), Prokop et al. used the CASY Cell Counter and Analyzer from Roche Applied Science (SIX: RO, ROG; OTCQX: RHHBY) to identify the specific anticancer properties of a therapeutic substance in Burkitt-like lymphoma cells (BJAB cells). In addition to using the CASY system for multi-parameter quality control of the cell cultures, ...

Clavis Pharma (OSE: CLAVIS), the Norwegian cancer drug development company, announces that its partner, Clovis Oncology, Inc., has recruited the first patient into a Phase II clinical study (CO-101-003 study) with CP-4126 (also known as CO-101). This trial will investigate the use of CP-4126 as a 2nd line treatment for advanced, metastatic pancreatic cancer in ...

The National Comprehensive Cancer Network® (NCCN®) recently updated the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines™) for Breast Cancer to affirm the recommendation regarding the use of bevacizumab (Avastin®, Genentech/Roche) in the treatment of metastatic breast cancer. The NCCN Guidelines Panel for Breast Cancer affirmed its existing recommendation of bevacizumab in combination with paclitaxel ...